Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant
Venkata Viswanadh Edara, Carson Norwood, Katharine Floyd, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Emerging SARS-CoV-2 variants of concern and potential intervention approaches
Jasmin Khateeb, Yuchong Li, Haibo Zhang
Critical Care (2021) Vol. 25, Iss. 1
Open Access | Times Cited: 228
An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
Shiho Tanaka, Gard Nelson, C. Anders Olson, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 64
Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants
Chunyan Yi, Xiaoyu Sun, Yixiao Lin, et al.
Genome Medicine (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 55
Hesitancy towards COVID-19 Vaccination among Healthcare Workers: A Multi-Centric Survey in France
C. Janssen, Alexis Maillard, Céline Bodelet, et al.
Vaccines (2021) Vol. 9, Iss. 6, pp. 547-547
Open Access | Times Cited: 50
Could live attenuated vaccines better control COVID-19?
Shinya Okamura, Hirotaka Ebina
Vaccine (2021) Vol. 39, Iss. 39, pp. 5719-5726
Open Access | Times Cited: 49
Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains
Nikhil Faulkner, Kevin W. Ng, Mary Wu, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 48
Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria
Egon A. Ozer, Lacy M. Simons, Moses Olubusuyi Adewumi, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 34
SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
Daniele Focosi, Marco Tuccori, Andreina Baj, et al.
Viruses (2021) Vol. 13, Iss. 7, pp. 1211-1211
Open Access | Times Cited: 38
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
Viviane M. Andrade, Aaron Christensen-Quick, Joseph Agnes, et al.
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 38
Structures of synthetic nanobody–SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction
Javeed Ahmad, Jiansheng Jiang, Lisa F. Boyd, et al.
Journal of Biological Chemistry (2021) Vol. 297, Iss. 4, pp. 101202-101202
Open Access | Times Cited: 35
Coincident rapid expansion of two SARS-CoV-2 lineages with enhanced infectivity in Nigeria
Egon A. Ozer, Lacy M. Simons, Moses Olubusuyi Adewumi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 34
Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in Nicotiana benthamiana Plant as a Vaccine Candidate against COVID-19
Tarlan Mamedov, Damla Yuksel, Merve Ilgın, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1337-1337
Open Access | Times Cited: 32
Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates
Qian He, Qunying Mao, Xiaozhong Peng, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 24
Neutralizing antibody: a savior in the Covid-19 disease
Sneh Lata Gupta, Rishi Kumar Jaiswal
Molecular Biology Reports (2022) Vol. 49, Iss. 3, pp. 2465-2474
Open Access | Times Cited: 23
Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
Lianlian Bian, Jianyang Liu, Fan Gao, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 23
A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine
Sonia Jangra, Jeffrey J. Landers, Raveen Rathnasinghe, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 31
Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters
Ankita Leekha, Arash Saeedi, K M Samiur Rahman Sefat, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
High avidity of vaccine-induced immunoglobulin G against SARS-CoV-2: potential relevance for protective humoral immunity
Georg Bauer
Exploration of Immunology (2022), pp. 133-156
Open Access | Times Cited: 16
Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains
Nikhil Faulkner, Kevin W. Ng, Mary Wu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 22
INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants
Viviane M. Andrade, Aaron Christensen-Quick, Joseph Agnes, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 19
Are convalescent plasma stocks collected during former COVID‐19 waves still effective against current SARS‐CoV‐2 variants?
Daniele Focosi, Massimo Franchini, Michael J. Joyner, et al.
Vox Sanguinis (2022) Vol. 117, Iss. 5, pp. 641-646
Closed Access | Times Cited: 12
Prime hAd5 Spike + Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike Variants
Peter A. Sieling, Thomas B. King, Raymond M.H. Wong, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 16
Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection
Luke Muir, Aneesa Jaffer, Chloe Rees-Spear, et al.
Kidney International Reports (2021) Vol. 6, Iss. 7, pp. 1799-1809
Open Access | Times Cited: 16
RBD mutations at the residues K417, E484, N501 reduced immunoreactivity with antisera from vaccinated and COVID-19 recovered patients
Dablu Lal Gupta, Jhasaketan Meher, Anjan Kumar Giri, et al.
Drug Target Insights (2024) Vol. 18, Iss. 1, pp. 20-26
Open Access | Times Cited: 1
Detection of Neutralizing Antibodies against SARS-CoV-2 Post-Vaccination in Health Care Workers of a Large Tertiary Hospital in Spain by Using a Rapid Test LFIC and sVNT-ELISA
José Tuells, Mónica Parra-Grande, Francisco J. Santos-Calle, et al.
Vaccines (2022) Vol. 10, Iss. 4, pp. 510-510
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top